Intellia Therapeutics (NTLA) Liabilities and Shareholders Equity (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Liabilities and Shareholders Equity data on file, last reported at $758.8 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 23.06% year-over-year to $758.8 million in Q1 2026; TTM through Mar 2026 was $3.4 billion, a 24.59% decrease from a year earlier, with the FY2025 full-year figure at $842.1 million, down 29.29% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $758.8 million, down from $842.1 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for NTLA reached as high as $1.5 billion in Q4 2022 and fell as low as $758.8 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $1.1 billion across 5 years, with a median of $1.2 billion in 2024.
• Across the five-year window, Liabilities and Shareholders Equity surged 67.78% in 2022 and slipped 29.29% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $1.5 billion in 2022, then fell by 14.42% to $1.3 billion in 2023, then retreated by 8.45% to $1.2 billion in 2024, then declined by 29.29% to $842.1 million in 2025, then dropped by 9.9% to $758.8 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $758.8 million in Q1 2026, $842.1 million in Q4 2025, and $925.3 million in Q3 2025.